Phillip Md Et Al Frost Acquires 150,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 150,000 shares of the business’s stock in a transaction that occurred on Friday, January 17th. The shares were purchased at an average price of $1.47 per share, for a total transaction of $220,500.00. Following the completion of the purchase, the chief executive officer now directly owns 213,186,477 shares of the company’s stock, valued at approximately $313,384,121.19. This trade represents a 0.07 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.48 per share, with a total value of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost acquired 125,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.59 per share, with a total value of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The stock was acquired at an average price of $1.56 per share, for a total transaction of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost acquired 199,072 shares of OPKO Health stock. The shares were acquired at an average cost of $1.53 per share, with a total value of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The stock was bought at an average price of $1.62 per share, for a total transaction of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost acquired 280,183 shares of OPKO Health stock. The shares were bought at an average price of $1.50 per share, with a total value of $420,274.50.

OPKO Health Price Performance

Shares of NASDAQ:OPK opened at $1.47 on Friday. OPKO Health, Inc. has a 1-year low of $0.86 and a 1-year high of $1.76. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The stock has a market cap of $1.00 billion, a P/E ratio of -7.74 and a beta of 1.63. The firm has a fifty day moving average price of $1.54 and a 200 day moving average price of $1.51.

Institutional Investors Weigh In On OPKO Health

Several hedge funds have recently made changes to their positions in the business. Rubric Capital Management LP increased its position in OPKO Health by 800.0% in the 2nd quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock valued at $55,528,000 after acquiring an additional 39,486,490 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of OPKO Health by 142.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after purchasing an additional 876,272 shares during the period. Clearline Capital LP acquired a new position in shares of OPKO Health in the third quarter valued at approximately $1,083,000. Squarepoint Ops LLC purchased a new stake in shares of OPKO Health during the second quarter worth approximately $592,000. Finally, Barclays PLC lifted its holdings in shares of OPKO Health by 154.5% during the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after purchasing an additional 329,870 shares during the period. Institutional investors and hedge funds own 64.63% of the company’s stock.

Analysts Set New Price Targets

OPK has been the topic of several research analyst reports. Barrington Research reiterated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research note on Friday, November 8th. StockNews.com downgraded OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Wednesday, January 8th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.